Amgen, Inc. has doubled the leadership of its research and development efforts, announcing on 14 December that it recruited former Novartis Institutes for BioMedical Research Inc. (NIBR) president Jay Bradner to serve as executive vice president of R&D and chief scientific officer. Current EVP of R&D David Reese remains in the company’s C-suite as executive vice president and chief technology officer.
Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D
Former Novartis Exec Rejoins Biopharma Industry
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
More from Leadership
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.